Methotrexate
Acute lymphoblastic leukemia, Meningeal leukemia, Non-Hodgkin lymphoma, Osteosarcoma, Breast cancer, Squamous cell carcinoma of the head and neck
Boxed warning
- WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS • Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Injection is contraindicated in pregnancy. Advise females and males of reproductive potential to use effective contraception [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ] . • Methotrexate Injection is ... (see full label)
High-alert medication
- Chemotherapeutic agents, parenteral (class); oral nononcologic methotrexate is also listed
Indications
- Acute lymphoblastic leukemia
- Meningeal leukemia
- Non-Hodgkin lymphoma
- Osteosarcoma
- Breast cancer
- Squamous cell carcinoma of the head and neck
Adult dosing
- rheumatoid arthritis: dose: 7.5; unit: mg; route: IM; interval: once weekly; fixed: true; labelExcerpt: Recommended starting dosage of 7.5 mg once weekly intramuscularly; adjust dose to achieve an optimal response. ( 2.10 )
- psoriasis: dose: 10; unit: mg; route: IM; interval: once weekly (range 10 mg to 25 mg); fixed: true; labelExcerpt: Recommended dosage of 10 mg to 25 mg once weekly intramuscularly or intravenously; adjust dose to achieve optimal response. Once achieved, reduce to lowest possible dosage. ( 2.12 )
- ectopic pregnancy single dose: Consult pharmacy/current label
Pediatric dosing
- polyarticular juvenile idiopathi: dose: 10; unit: mg/m2; route: SC; interval: once weekly; fixed: true; labelExcerpt: Recommended starting dosage of 10 mg/m 2 once weekly subcutaneously or intramuscularly; adjust dose to achieve an optimal response. ( 2.11 )
Renal adjustment
- Consult pharmacy/current label
Hepatic adjustment
- Consult pharmacy/current label
Contraindications
- Severe hypersensitivity to methotrexate
- Pregnancy (non-neoplastic diseases)
Clinical pearls
- Administer folic or folinic acid to reduce risk of adverse reactions.
- Verify pregnancy status in females of reproductive potential prior to starting.
- Use only preservative-free formulations for intrathecal use or in neonates.
- Monitor for myelosuppression, infections, and renal/hepatic/pulmonary toxicity.
Source and review
- DailyMed label (methotrexate), Set ID 0e30eaef-5a09-4104-8a11-c32933eadeab, effective 2026-10-29; ACOG Practice Bulletin No. 193 (2018, PMID 29470343) - paywalled; abstract has no dose; not verified. Last reviewed: 2026-11-11
RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties